Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...8182838485868788899091...401402»
  • ||||||||||  Journal:  Gripwise (Pubmed Central) -  Dec 4, 2023   
    The correlation of the Gripwise with the Jamar was confirmed in aged inpatients. However, lower values recorded with the Gripwise require alternate cutoffs for a relevant low HGS diagnosis.
  • ||||||||||  Review, Journal:  Ubiquitin-proteasome pathway in skeletal muscle atrophy. (Pubmed Central) -  Dec 4, 2023   
    Furthermore, by drawing from recent scholarly advancements, we draw associations between the ubiquitin-proteasome pathway and specific pathological conditions linked to muscle atrophy. Our exploration seeks to shed light on the ubiquitin-proteasome pathway's significance in skeletal muscle dynamics, aiming to pave the way for innovative therapeutic strategies against muscle atrophy and affiliated muscle disorders.
  • ||||||||||  Journal:  Validation of SARC-F-Proxy for the Screening of Sarcopenia in Older Patients with Cognitive Impairment. (Pubmed Central) -  Dec 4, 2023   
    the proxy-reported SARC-F questionnaire can be applied as a surrogate for the SARC-F in the screening of sarcopenia in hospitalised community-dwelling older people with known or suspected cognitive impairment. Second, the results in this study suggest a higher reliability when the proxy-reported questionnaire is performed by the formal caregiver.
  • ||||||||||  Journal:  Muscle quality an evolving concept. (Pubmed Central) -  Dec 4, 2023   
    Biological and adaptative changes to ageing must be considered when interpretation of muscle quality assessment is done in a clinical or research context. One of the conditions that requires an adequate homologation in terminology is sarcopenia, to establish definition and cut-off points.
  • ||||||||||  Trial completion, Trial completion date:  Impact of Fish Oil Dose on Tissue Content and Function (clinicaltrials.gov) -  Dec 4, 2023   
    P=N/A,  N=28, Completed, 
    Co-MS is prevalent in long-term nursing care facilities; thus, healthcare workers should pay attention to relevant factors to identify patients at risk of co-MS and to provide appropriate care and intervention. Active, not recruiting --> Completed | Trial completion date: Feb 2024 --> Jun 2023
  • ||||||||||  Trial completion date, Trial primary completion date:  Muscular Deficits of Diabetic Myopathy (clinicaltrials.gov) -  Dec 4, 2023   
    P=N/A,  N=108, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Feb 2024 --> Jun 2023 Trial completion date: Nov 2024 --> Dec 2025 | Trial primary completion date: Nov 2024 --> Sep 2025
  • ||||||||||  Journal:  Editorial: Sarcopenia and frailty: the role of physical activity for better aging. (Pubmed Central) -  Dec 3, 2023   
    With the increase in the TG/HDL-C ratio, the relative grip strength of older adults decreased significantly, indicating that the TG/HDL-C ratio could be closely monitored in the older adult population and may be associated with the prevention and control of sarcopenia. No abstract available
  • ||||||||||  Review, Journal:  Frailty and sarcopenia: A bibliometric analysis of their association and potential targets for intervention. (Pubmed Central) -  Nov 30, 2023   
    Their pathogenesis involved cellular aging and endocrine metabolism regulation pathways, including AMPK, cell senescence, and the endocrine resistance pathway. This study identified an intimate correlation between frailty and sarcopenia in pathogenesis, prevention, and treatment measures, establishing a foundation for exploring shared prevention and treatment strategies for these two disorders.
  • ||||||||||  Journal:  Impact of Sarcopenia on Survival of Patients With Malignant Salivary Glands Tumors. (Pubmed Central) -  Nov 30, 2023   
    The early detection of sarcopenia in patients with negative prognostic factors could be used to implement the support therapeutic strategies aimed at restore the clinical conditions of the patients. Sarcopenia may be routinely investigated before surgery to suggest the implementation of precautionary therapeutic strategies to improve the standard treatment response, reducing possible complications.
  • ||||||||||  Review, Journal:  Targeting Epigenetic Regulators with HDAC and BET Inhibitors to Modulate Muscle Wasting. (Pubmed Central) -  Nov 29, 2023   
    Thus, epigenetic drugs targeting HDACs and BET proteins may emerge as promising strategies to reverse the catabolic phenotype associated with cachexia and sarcopenia. Further preclinical studies are warranted to delve deeper into the molecular mechanisms associated with the functions of HDACs and BET proteins in muscle atrophy and to establish whether their epigenetic inhibitors represent a prospective therapeutic avenue to alleviate muscle wasting.
  • ||||||||||  Review, Journal:  The Molecular Role of Polyamines in Age-Related Diseases: An Update. (Pubmed Central) -  Nov 29, 2023   
    In this review, we provide a new perspective on the participation of Pas in the cellular and molecular processes related to age-related diseases, focusing our attention on important degenerative diseases such as Alzheimer?s disease, Parkinson?s disease, osteoarthritis, sarcopenia, and osteoporosis. This new perspective leads us to propose that Pas function as novel biomarkers for age-related diseases, with the main purpose of achieving new molecular alternatives for healthier aging.
  • ||||||||||  Review, Journal:  Muscle-bone crosstalk via endocrine signals and potential targets for osteosarcopenia-related fracture. (Pubmed Central) -  Nov 29, 2023   
    However, no pharmacological agent is available to treat fracture patients with osteosarcopenia. This review summarizes the role of several myokines and osteokines in the development and treatment of osteosacropenia and fracture, as well as discusses their potential as intervention targets for osteosarcopenia-related fracture, which provides a novel and promising strategy for future osteosarcopenia-related fracture treatment.
  • ||||||||||  Journal:  Correlation between MRI-based spinal muscle parameters and the vertebral bone quality score in lumbar fusion patients. (Pubmed Central) -  Nov 29, 2023   
    This review summarizes the role of several myokines and osteokines in the development and treatment of osteosacropenia and fracture, as well as discusses their potential as intervention targets for osteosarcopenia-related fracture, which provides a novel and promising strategy for future osteosarcopenia-related fracture treatment. After adjusting for age and BMI, a significant negative correlation was seen between the VBQ score and psoas FCSA at L3 (?